{
    "clinical_study": {
        "@rank": "99038", 
        "arm_group": {
            "arm_group_label": "Cohort"
        }, 
        "brief_summary": {
            "textblock": "This observational study will evaluate the efficacy, safety and patient reported quality of\n      life of palliative first-line Perjeta (pertuzumab) in combination with Herceptin\n      (trastuzumab) in patients with HER2-positive advanced breast cancer (metastatic or locally\n      recurrent, inoperable) who relapsed after completed adjuvant Herceptin therapy.\n      Additionally, information on selection criteria of breast cancer patients treated first-line\n      with Perjeta, Herceptin and chemotherapy and their treatment duration will be collected and\n      analyzed. Data will be collected from eligible patients for up to 20 months of treatment and\n      24 months of follow-up."
        }, 
        "brief_title": "HELENA Study: An Observational Study of Perjeta (Pertuzumab) in First-Line Treatment in Patients With Her2-Positive Advanced Breast Cancer After Adjuvant Herceptin Therapy", 
        "completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female adult patients, >/= 18 years of age\n\n          -  HER2-positive advanced breast cancer (metastatic or locally recurrent, inoperable)\n             relapsing after completed adjuvant Herceptin therapy\n\n          -  Indication for first-line treatment with Perjeta in combination with Herceptin and\n             chemotherapy according to the Summary of Product Characteristics\n\n          -  Prior Herceptin therapy as systemic adjuvant treatment (postoperative treatment in a\n             potentially curable setting); additional upfront neoadjuvant Herceptin therapy is\n             allowed\n\n          -  No prior chemotherapy and/or immunotherapy for advanced (metastatic or locally\n             recurrent, inoperable) HER2-positive breast cancer\n\n        Exclusion Criteria:\n\n          -  Pregnant or breastfeeding women\n\n          -  Contraindications to Perjeta, Herceptin or concomitant chemotherapy according to the\n             Summary of Product Characteristics\n\n          -  No Herceptin treatment for early breast cancer in the adjuvant setting"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Female patients with HER2-positive advanced breast cancer (metastatic or locally\n        recurrent, inoperable)who relapsed after adjuvant Herceptin therapy, with indication for\n        treatment with Perjeta in combination with Herceptin"
            }
        }, 
        "enrollment": {
            "#text": "478", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01777958", 
            "org_study_id": "ML28750"
        }, 
        "intervention_browse": {
            "mesh_term": "Trastuzumab"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Frankfurt", 
                    "country": "Germany", 
                    "zip": "60431"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_groups": "1", 
        "official_title": "Noninterventional Study - Advanced HER2-positive Breast Cancer (Metastatic or Locally Recurrent, Inoperable): First-Line Treatment With PERJETA After Adjuvant Herceptin Therapy (HELENA)", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: ML28750 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Median progression-free survival in routine clinical practice", 
            "safety_issue": "No", 
            "time_frame": "approximately 7.5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01777958"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Dosage/schedule: Initiation/duration/modification/discontinuation of Perjeta administration", 
                "safety_issue": "No", 
                "time_frame": "approximately 7.5 years"
            }, 
            {
                "measure": "Clinical/demographic patients characteristics at initiation of treatment", 
                "safety_issue": "No", 
                "time_frame": "approximately 7.5 years"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 7.5 years"
            }, 
            {
                "measure": "Patient reported outcome: Quality of life (FACT B questionnaire)", 
                "safety_issue": "No", 
                "time_frame": "approximately 7.5 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}